Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1Advanced Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 34Busulfan 32fludarabine phosphate 29Cyclosporine 24Mycophenolic Acid 22Peripheral Blood Stem Cell Transplantation 21Whole-Body Irradiation 19Antilymphocyte Serum 19Tacrolimus 15Methotrexate 15Cytarabine 15fludarabine 14Melphalan 14Cord Blood Stem Cell Transplantation 14Radiotherapy 13Filgrastim 12Methylprednisolone 9Granulocyte Colony-Stimulating Factor 9Etoposide 7Thiotepa 6thymoglobulin 5sargramostim 5Idarubicin 5Cyclosporins 5Clofarabine 5Azacitidine 5merphos 4Gemtuzumab 4Decitabine 4Arsenic Trioxide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Refractory, with Excess of Blasts × paricalcitol × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡